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Abstract: Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with
diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with
cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). Although
studies focus mainly on the contribution of BCL-2, here we also investigate the contribution of other
anti-apoptotic proteins to CHOP-therapy resistance in DLBCL. Functional dynamic BCL-2 homology
(BH)3 profiling was applied to DLBCL cell lines upon CHOP treatment or single CHOP compounds.
Cell-specific anti-apoptotic dependencies were validated with corresponding BH3-mimetics. We found
high expression of anti-apoptotic BCL-2, MCL-1, and BCL-XL in DLBCL cell lines and patients.
CHOP treatment resulted in both enhanced and altered anti-apoptotic dependency. Enhanced
sensitivity to different BH3-mimetics after CHOP treatment was confirmed in specific cell lines,
indicating heterogeneity of CHOP-induced resistance in DLBCL. Analysis of single CHOP compounds
demonstrated that similar changes could also be induced by doxorubicin or vincristine, providing
evidence for clinical combination therapies of doxorubicin or vincristine with BH3-mimetics in DLBCL.
In conclusion, we show for the first time that CHOP treatment induces increased anti-apoptotic
dependency on MCL-1 and BCL-XL, and not just BCL-2. These results provide new perspectives for
the treatment of CHOP-resistant DLBCL and underline the potential of BH3 profiling in predicting
therapy outcomes.
Keywords: diffuse large B-cell lymphoma; CHOP; BCL-2; MCL-1; BCL-XL; venetoclax; S63845
1. Introduction
The B-cell lymphoma 2 (BCL-2) family of proteins is a group of pro- and anti-apoptotic proteins
with key roles in the regulation of intrinsic apoptosis. Proteins of the BCL-2 family share a general
structure of one or more BCL-2 homology (BH) domains, of which expression of the BH3 domain is a
universally shared feature. Expression of this BH3 domain is essential for protein-protein interactions,
thereby allowing dimerization of pro-apoptotic sensitizer proteins (e.g., BAD, NOXA and HRK)
with anti-apoptotic proteins (e.g., BLC-2, BCL-XL, MCL-1 and BCL-W). This interaction leaves the
pro-apoptotic activator proteins (e.g., BID and BIM) free to interact with the effector proteins (e.g., BAX
and BAK) to induce pore formation and cytochrome c release from the mitochondria, thus promoting
apoptosis [1]. Dysregulated expression of several important anti-apoptotic proteins, such as BCL-2,
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plays a crucial role in carcinogenesis and anti-cancer therapy resistance [2]. The specific anti-apoptotic
dependency in a particular cancer cell is often unknown, and cancer cells may adapt their anti-apoptotic
dependencies when exposed to particular apoptosis-inducing therapies (e.g., chemotherapy) to further
facilitate therapy resistance [3].
In diffuse large B-cell lymphoma (DLBCL), overexpression of the anti-apoptotic protein BCL-2
is correlated with adverse survival in patients treated with standard rituximab, cyclophosphamide,
vincristine, doxorubicin, and prednisone (R-CHOP) [4]. In DLBCL patients, BCL-2 is commonly
overexpressed due to either a t(14;18) chromosomal translocation or to BCL-2 amplification or
transcriptional upregulation. The t(14;18) translocation is more common, at 20%–30% of cases, in the
germinal center (GCB) molecular subtype, whereas BCL-2 amplification is found in 8%–30% of the
activated B-cell (ABC) subtype [5,6].
Inhibition of the anti-apoptotic activity of BCL-2 has been suggested as a promising strategy
for treatment [7], however, a single-agent phase I study of the specific BCL-2 inhibitor venetoclax in
relapsed or refractory DLBCL reported limited efficacy [8]. On the other hand, promising results,
including an overall response of 87.5% and a complete response (CR) of 79.2%, were reported in a
phase I trial of venetoclax combined with R-CHOP as first-line treatment in non-Hodgkin lymphomas,
including DLBCL [9]. However, other studies have reported that apoptotic resistance in DLBCL can
be acquired through proteins other than BCL-2 [10]. Analysis of primary DLBCL patient samples
treated with BH3 mimetic drugs (BCL-2 inhibitor and MCL-1 inhibitor) showed that patients could be
subdivided into BCL-2-sensitive or MCL-1-sensitive subgroups [10]. However, the effect of standard
(prolonged) CHOP treatment itself on DLBCL-specific pro- and anti-apoptotic signaling is currently
unknown. To this end, we studied the effect of CHOP therapy on anti-apoptotic dependency in DLBCL
using functional dynamic BH3 profiling [11]. By employing functional dynamic BH3 profiling, we
compared the profiles of eight DLBCL cell lines before and after CHOP treatment and thus determined
the change in dependency on anti-apoptotic proteins. Our results showed that CHOP resistance is
not exclusively mediated through BCL-2, but by multiple other anti-apoptotic proteins. These results
highlight the heterogeneity of anti-apoptotic dependency in DLBCL, which likely depends on other
anti-apoptotic proteins in addition to BCL-2. These results could have implications for clinical trials
evaluating efficacy of BH3 mimetics.
2. Results
2.1. DLBCL Cells Are Dependent on BCL-2 or MCL-1, but Not BCL-XL
BCL-2 protein overexpression is an important predictive and prognostic marker in DLBCL patients
(4). We first validated the importance of different anti-apoptotic BCL-2 family protein expression
in our representative DLBCL cell line panel with different genetic backgrounds (5 GCB and 3 ABC)
and correlated anti-apoptotic protein expression to their functional anti-apoptotic dependency as
determined by BH3 profiling (Figure 1, Figures S1 and S2).
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Figure 1. Expression and dependency on anti-apoptotic proteins in diffuse large B-cell lymphoma 
(DLBCL) cell lines. Overview of eight DLBCL cell lines with their (A) cell of origin (COO) 
classification, and translocation (TRANS) or amplification (AMP) status for B-cell lymphoma 2 (BCL-
2) or MYC. (B) Protein expression of anti-apoptotic proteins encoded by BIM, MCL-1, BCL-XL and 
BCL-2. (C) BCL-2 homology (BH)3 profile peptide response as measured by mitochondrial outer 
membrane permeabilization (MOMP) (n = 3). Values marked in red were below 10% MOMP and 
therefore classified as unresponsive, whereas values marked in green were above 10% MOMP and 
classified as responsive. (D) The half maximal inhibitory concentration (IC50) values for venetoclax 
(BCL-2i; 48 h), navitoclax (BCL-2/XL/Wi; 48 h), S63845 (MCL-1i; 48 h) and cyclophosphamide, 
vincristine, doxorubicin, prednisolone (CHOP) chemotherapy (72 h) (n = 3). IC50 values below 1 µM 
(for venetoclax, navitoclax, or S63845) or below 5 µg/mL (for CHOP) were deemed sensitive and 
marked in red, whereas values above 1 µM (for venetoclax, navitoclax, or S63845) or above 5 µg/mL 
(for CHOP) were deemed insensitive and therefore marked in green. 
All DLBCL cell lines showed protein expression of apoptotic activator BIM, indicating that cells 
are capable of undergoing apoptosis (Figure 1B). Variable protein expression of anti-apoptotic 
proteins MCL-1, BCL-XL, and BCL-2 was observed in the DLBCL cell lines, indicating that cells 
employed different and/or multiple anti-apoptotic proteins to protect from apoptosis. In most cases, 
cells with acquired translocation or amplification of the BCL-2 protein showed high expression of 
BCL-2, with the exception of cell line SUDHL-10, which showed high expression of MCL-1 instead 
(Figure 1A–B). Next, we performed BH3 profiling to determine the intrinsic functional dependency 
of cells on specific anti-apoptotic proteins (Figures 1C and S1). BH3 profiling revealed that all cells 
showed a strong response to the BIM peptide (min 71%; max 95%), which confirms previous results 
for BIM protein expression (Figure 1B). In addition, cell lines with high BCL-2 protein expression 
showed a mitochondrial response to the BAD peptide (min 30%; max 93%), indicating functional 
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All DLBCL cell lines showed protein expression of apoptotic activator BIM, indicating that
cells are capable of undergoing apoptosis (Figure 1B). Variable protein expression of anti-apoptotic
proteins MCL-1, BCL-XL, and BCL-2 was observed in the DLBCL cell lines, indicating that cells
employed different and/or multiple anti-apoptotic proteins to protect from apoptosis. In most cases,
cells with acquired translocation or amplification of the BCL-2 protein showed high expression of
BCL-2, with the exception of cell line SUDHL-10, which showed high expression of MCL-1 instead
(Figure 1A,B). Next, we performed BH3 profiling to determine the intrinsic functional dependency of
cells on specific anti-apoptotic proteins (Figure 1C and Figure S1). BH3 profiling revealed that all cells
showed a strong response to the BIM peptide (min 71%; max 95%), which confirms previous results
for BIM protein expression (Figure 1B). In addition, cell lines with high BCL-2 protein expression
showed a mitochondrial response to the BAD peptide (min 30%; max 93%), indicating functional
dependency on BCL-2. Cell lines SUDHL-5 and SUDHL-10, which were not dependent on BCL-2,
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instead showed high response to the NOXA/MS1 peptides (min 17%; max 68%), indicating functional
MCL-1 dependency, which matches with relatively high MCL-1 protein expression (Figure 1B). Together,
these data demonstrate that DLBCL cells were either exclusively dependent on BCL-2 or MCL-1, but
not on BCL-XL or multiple anti-apoptotic proteins simultaneously, despite expression of multiple
anti-apoptotic proteins.
2.2. DLBCL Patients Show Simultaneous Expression of BCL-2, BCL-XL, and MCL-1
To validate that, like the DLBCL cell lines, DLBCL patients also show simultaneous expression
of BCL-2, BCL-XL, and MCL-1, we performed immunohistochemistry staining on 55 DLBCL patient
tissues (Table 1 and Figure 2).
Table 1. Immunohistochemistry of BCL-2, BCL-XL and MCL-1 in DLBCL patients (n = 55).
DLBCL Cases BCL-2 Negative (n = 21) BCL-2 Positive (n = 34)
BCL-XL negative 0/21 (0%) 1/34 (3%)
BCL-XL positive 21/21 (100%) 33/34 (97%)
MCL-1 negative 1/21 (5%) 2/34 (6%)
MCL-1 positive 20/21 (95%) 32/34 (94%)
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Figure 2. Immunohistochemistry staining for BCL-2, MCL-1, and BCL-XL in DLBCL. (A) 
Representative example of a BCL-2 negative DLBCL patient with positive staining for MCL-1 (B) and 
BCL-XL (C). (D) Representative example of a BCL-2 positive DLBCL patient with positive staining 
for MCL-1 (E) and BCL-XL (F). All images were captured at 200× magnification.  
Staining for the anti-apoptotic proteins revealed 34/55 patients (62%) stained positive for BCL-2, 
55/55 (100%) stained positive for BCL-XL, and 52/55 (95%) stained positive for MCL-1. In addition, one 
case (2%) was positive for only one anti-apoptotic protein (BCL-XL), 22 cases (40%) were positive for 
two out of three anti-apoptotic proteins, and 32 cases (58%) were positive for all three anti-apoptotic 
proteins. Of the BCL-2 negative cases, 21/21 (100%) were positive for BCL-XL and 20/21 (95%) were 
positive for MCL-1 (Table 1 and Figure 2A–C). A similar trend was observed in the BCL-2 positive cases, 
Figure 2. Immunohistochemistry staining for BCL-2, MCL-1, and BCL-XL in DLBCL. (A) Representative
example of a BCL-2 negative DLBCL patient with positive staining for MCL-1 (B) a d BCL-XL (C).
(D) R presentative example of a BCL-2 positive DLBCL pa ien with positive staining for MCL-1 (E)
and BCL-XL (F). All images wer captured at 200×magnification.
Staining for the anti-apoptotic proteins revealed 34/55 patients (62%) stained positive for BCL-2,
55/55 (100%) stained positive for BCL-XL, and 52/55 (95%) stained positive for MCL-1. In addition, one
case (2%) was positive for only one anti-apoptotic protein (BCL-XL), 22 cases (40%) were positive for
two out of three anti-apoptotic proteins, and 32 cases (58%) were positive for all three anti-apoptotic
proteins. Of the BCL-2 negative cases, 21/21 (100%) were positive for BCL-XL and 20/21 (95%) were
positive for MCL-1 (Table 1 and Figure 2A–C). A similar trend was observed in the BCL-2 positive cases,
of which 33/34 (97%) stained positive for BCL-XL and 32/34 (94%) were positive for MCL-1 (Table 1 and
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Figure 2D–F). Together, these data demonstrate that there are high levels and simultaneous expression
of the multiple anti-apoptotic proteins, which strongly mirror our findings in the DLBCL cell lines.
2.3. BCL-2 Expression Predicts Sensitivity to Venetoclax and CHOP
Next, we correlated the intrinsic functional anti-apoptotic dependency of our cells to the sensitivity
for anti-apoptotic inhibitors venetoclax (BCL-2i), S63845 (MCL-1i), navitoclax (BCL-2/BCL-XL/BCL-Wi),
and CHOP chemotherapy (Figure 3).
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Figure 3. Correlation between BH3 response to BAD, NOXA, and MS1 peptides and sensitivity to
anti-apoptotic inhibitors venetoclax (BCL-2i), navitoclax (BCL-2/XL/Wi), S63845 (MCL-1i), and CHOP
chemotherapy in DLBCL cell lines. (A) Correlation between venetoclax IC50 versus BAD peptide
response (%MOMP). (B) Correlation between navitoclax IC50 versus BAD peptide response (%MOMP).
(C) Correlation between CHOP IC50 versus BAD peptide response (%MOMP). (D) Correlation between
S63845 IC50 versus NOXA peptide response (%MOMP). (E) Correlation between S63845 IC50 versus
MS1 peptide response (%MOMP). (F) Correlation between CHOP IC50 versus NOXA peptide response
(%MOMP). Data were plotted as the mean of n = 3. Correlation was analyzed using Spearman’s
correlation. Cell lines without a ‘double hit’ (MYC/BCL2) status are represented by open symbols (
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We found a negative correlation between venetoclax IC50 and the BAD response (r = −0.810; p = 
0.022) (Figure 3A), but not for navitoclax and BAD response (r = −0.575; p = 0.143) (Figure 3B), 
indicating that a high BAD response is predictive of a low venetoclax IC50 and thus high sensitivity 
to BCL-2 inhibition. This discrepancy between venetoclax and navitoclax is likely caused by the 
individual potency of the inhibitors, as venetoclax has a very high sensitivity for BCL-2 (Ki <0.01 nM) 
compared to navitoclax (Ki ≤ 0.5 nM for BCL-XL and Ki ≤ 1 nM for BCL-2). On the other hand, cell 
lines with low or absent BCL-2 protein expression (SUDHL-2, SUDHL-5, and SUDHL-10) had a 
significantly higher IC50 for venetoclax (median IC50 11 µM) compared to cell lines with high BCL-2 
protein expression (OCI-LY3, U-2932, SUDHL-4, SUDHL-6, and SC-1; median IC50 for venetoclax of 
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expression and functional BH3 profiling can predict sensitivity, whereas only functional BH3 
profiling can predict sensitivity to S63845. Following these results, we correlated anti-apoptotic 
protein expression and the functional BH3 profiles to CHOP chemotherapy sensitivity and found 
that absence of BCL-2 protein expression was associated with low CHOP IC50 (median IC50 0.44 
µg/mL) (Figures 1D and S3D), while high BCL-2 protein expression was associated with high CHOP 
IC50 values (median 5 µg/mL). These results are similar to findings in DLBCL patients, in which BCL-
2 overexpression (with or without MYC rearrangement) are associated with poor survival in patients 
treated with R-CHOP (4). This correlation trend was also observed for the functional BCL-2 BH3 
profile and CHOP response, in which a high BAD response showed a trend towards high CHOP IC50 
values (r = 0.595; p = 0.1323) (Figure 3E). No correlation was observed with CHOP sensitivity and 
MCL-1 protein expression (Figure S3E) or the functional NOXA BH3 profile (Figure 3F). Taken 
together, these results show that in untreated/treatment naïve cells, both high BCL-2 expression and 
functional BH3 profiling for BAD can predict sensitivity to venetoclax and CHOP. However, in the 
situation that cells show no expression of BCL-2, functional BH3 profiling should be applied to 
determine sensitivity to specific anti-apoptotic inhibitors. 
2.4. CHOP Chemotherapy Alters Dependency on Anti-Apoptotic Proteins 
Based on previous experiments, we have established that DLBCL cells can express multiple anti-
apoptotic proteins simultaneously, but usually show functional dependency on either BCL-2 or MCL-
1. However, it remains unclear if standard CHOP treatment has the ability to alter or shift this 
dependency on anti-apoptotic proteins. To test this hypothesis, we employed dynamic BH3 profiling, 
which compares the BH3 profiles of treated and untreated cells and plots the differences in response 
to each BH3 peptide, revealing the altered anti-apoptotic dependencies after specific treatments. 
Dynamic BH3 profiling of CHOP-treated DLBCL cell lines revealed an enhanced mitochondrial 
response to the BIM peptide (OCI-LY3, SUDHL-5, SUDHL-6, SUDHL-10, and SC-1), indicating that 
cells had become more primed for apoptosis (Figure S4). 
In addition, five of the eight cell lines (OCI-LY3, U-2932, SUDHL-2, SUDHL-4, SUDHL-6, and 
SC-1) showed a mitochondrial response to the BAD peptide (Figure 4A), which could indicate that 
cells had become more dependent on BCL-2 after CHOP treatment. Apart from responses to BAD, 
three cell lines showed a strong response to the HRK peptide (SUDHL-2, OCI-LY3, and SUDHL-4) 
(Figure 4B), which could indicate enhanced dependency on BCL-XL, and two cell lines (SUDHL-5 
and SUDHL-10) showed a response to the NOXA peptide (Figure 4C), which could indicate enhanced 
dependency on MCL-1 after CHOP treatment. Combined, these data suggest that CHOP treatment 
altered the BCL-2 dependency of cell lines OCI-LY3 and SUDHL-4 towards BCL-XL dependency, and 
made the anti-apoptotic independent cell line SUDHL-2 dependent on BCL-XL (Figure 4D). In the 
other cell lines, the cell specific anti-apoptotic dependency remained the same, however, it was 
and cell lines with a ‘double hit’ status by closed symbols (
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2.4. CHOP Chemotherapy Alters Dependency on Anti-Apoptotic Proteins 
Based on previous experiments, we have established that DLBCL cells can express multiple anti-
apoptotic proteins simultaneously, but usually show functional dependency on either BCL-2 or MCL-
1. However, it remains unclear if standard CHOP treatment has the ability to alter or shift this 
dependency on anti-apoptotic proteins. To test this hypothesis, we employed dynamic BH3 profiling, 
which compares the BH3 profiles of treated and untreated cells and plots the differences in response 
to each BH3 peptide, revealing the altered anti-apoptotic dependencies after specific treatme ts. 
Dynamic BH3 profiling of CHOP-treated DLBCL cell lines revealed an enhanced mitochondrial 
response to the BIM peptide (OCI-LY3, SUDHL-5, SUDHL-6, SUDHL-10, and SC-1), indicating that 
cells had become more primed for apoptosis (Figure S4). 
In addition, five of the eight cell lines (OCI-LY3, U-2932, SUDHL-2, SUDHL-4, SUDHL-6, and 
SC-1) showed a mitochondrial response to the BAD peptide (Figure 4A), which could indicat  that 
cells had become more dependent on BCL-2 after CHOP treatment. Apart from responses to BAD, 
three cell lines showed a strong response to the HRK peptide (SUDHL-2, OCI-LY3, and SUDHL-4) 
(Figure 4B), which could indicate enhanced dependency on BCL-XL, and two cell lines (SUDHL-5 
and SUDHL-10) showed a response to the NOXA peptide (Figure 4C), which could indicate enhanc d 
dependency on MCL-1 after CHOP treatment. Combined, these data suggest that CHOP treatment 
altered the BCL-2 dependency of cell lines OCI-LY3 and SUDHL-4 towards BCL-XL dependency, and 
made the anti-apoptotic independent cell line SUDHL-2 dependent on BCL-XL (Figure 4D). In the 
other cell lines, the cell specific anti-apoptotic dependency remained the same, however, it was 
it the hig est BCL-2 protein
expres ion (U-2932 and SC-1) are represented by an asterisk (
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2.4. CHOP Chemotherapy Alters Dependency on Anti-Apoptotic Proteins 
Based on previous experiments, we have stablished that DLBCL cells can express multiple anti-
apoptotic proteins imultaneously, but usually show functional dependency on either BCL-2 or MCL-
1. However, it remains unclear if standard CHOP treatment has the abil ty to alter or shift this 
dependency on anti-apoptotic proteins. To test his hypothesi , we mployed dynamic BH3 profil ng, 
which compares the BH3 profiles of treated and untreated cells and plots the differences in resp nse 
to each BH3 peptide, revealing the altered anti-apoptotic dependencies after specif c treatments. 
Dynamic BH3 profil ng of CHOP-treated DLBCL cell lines revealed an enhanced mitochondrial 
response to the BIM peptide (OCI-LY3, SUDHL-5, SUDHL-6, SUDHL-10, and SC-1), indicating that 
cells had become more primed for apoptosi  (Figure S4). 
In ad it on, five of the eight cell ines (OCI-LY3, U-2932, SUDHL-2, SUDHL-4, SUDHL-6, and 
SC-1) showed a mitochondrial response to the BAD peptide (Figure 4A), which could indicate that 
cells had become more dependent on BCL-2 after CHOP treatment. Apart from responses to BAD,
thre  cell ines howed a strong response to the HRK peptide (SUDHL-2, OCI-LY3, and SUDHL-4) 
(Figure 4B), which could indicate enhanced dependency on BCL-XL, and two cell ines (SUDHL-5 
and SUDHL-10) showed a response to the NOXA peptide (Figure 4C), which could indicate nhanced 
dependency on MCL-1 after CHOP treatment. Combined, these data sug est hat CHOP treatment 
altered the BCL-2 dependency of cell lines OCI-LY3 and SUDHL-4 towards BCL-XL dependency, and 
made the anti-apoptotic independent cell ine SUDHL-2 dependent on BCL-XL (Figure 4D). In the
other cell lines, the cell specif c anti-apoptotic dependency remained the same, however, it was 
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We found a negative correlation between venetoclax IC50 and the BAD response (r = −0.810;
p = 0.022) (Figure 3A), but not for navitoclax and BAD response (r = −0.575; p = 0.143) (Figure 3B),
indicating that a high BAD response is predictive of a low venetoclax IC50 and thus high sensitivity
to BCL-2 inhibition. This discrepancy between venetoclax and navitoclax is likely caused by the
individual potency of the inhibitors, as venetoclax has a very high sensitivity for BCL-2 (Ki < 0.01 nM)
compared to navitoclax (Ki ≤ 0.5 nM for BCL-XL and Ki ≤ 1 nM for BCL-2). On the other hand,
cell lines with low or absent BCL-2 protein expression (SUDHL-2, SUDHL-5, and SUDHL-10) had a
significantly higher IC50 for venetoclax (median IC50 11 µM) compared to cell lines with high BCL-2
protein expression (OCI-LY3, U-2932, SUDHL-4, SUDHL-6, and SC-1; median IC50 for venetoclax of
0.17 µM; p = 0.0004) (Figure 1D and Figure S3A). In addition, functional BH3 profiling for NOXA
(r = −0.903; p = 0.005) and MS1 (r = −0.756; p = 0.041) showed a strong correlation with sensitivity
to S63845 (Figure 3C,D), whereas no correlation could be established between the S63845 sensitivity
and MCL-1 protein expression (Figure S3C). These results demonstrate that, for venetoclax, both
BCL-2 protein expression and functional BH3 profiling can predict sensitivity, whereas only functional
BH3 profiling can predict sensitivity to S63845. Following these results, we correlated anti-apoptotic
protein expression and the functional BH3 profiles to CHOP chemotherapy sensitivity and found that
absence of BCL-2 protein expression was associated with low CHOP IC50 (median IC50 0.44 µg/mL)
(Figure 1D and Figure S3D), while high BCL-2 protein expression was associated with high CHOP IC50
values (median 5 µg/mL). These results are similar to findings in DLBCL patients, in which BCL-2
overexpression (with or without MYC rearrangement) are associated with poor survival in patients
treated with R-CHOP (4). This correlation trend was also observed for the functional BCL-2 BH3 profile
and CHOP response, in which a high BAD response showed a trend towards high CHOP IC50 values
(r = 0.595; p = 0.1323) (Figure 3E). No correlation was observed with CHOP sensitivity and MCL-1
protein expression (Figure S3E) or the functional NOXA BH3 profile (Figure 3F). Taken together, these
results show that in untreated/treatment naïve cells, both high BCL-2 expression and functional BH3
profiling for BAD can predict sensitivity to venetoclax and CHOP. However, in the situation that cells
show no expression of BCL-2, functional BH3 profiling should be applied to determine sensitivity to
specific anti-apoptotic inhibitors.
2.4. CHOP Chemotherapy Alters Dependency on Anti-Apoptotic Proteins
Based on previous experiments, we have established that DLBCL cells can express multiple
anti-apoptotic proteins simultaneously, but usually show functional dependency on either BCL-2 or
MCL-1. However, it remains unclear if standard CHOP treatment has the ability to alter or shift this
dependency on anti-apoptotic proteins. To test this hypothesis, we employed dynamic BH3 profiling,
which compares the BH3 profiles of treated and untreated cells and plots the differences in response to
each BH3 peptide, revealing the altered anti-apoptotic dependencies after specific treatments. Dynamic
BH3 profiling of CHOP-treated DLBCL cell lines revealed an enhanced mitochondrial response to the
BIM peptide (OCI-LY3, SUDHL-5, SUDHL-6, SUDHL-10, and SC-1), indicating that cells had become
more primed for apoptosis (Figure S4).
In addition, five of the eight cell lines (OCI-LY3, U-2932, SUDHL-2, SUDHL-4, SUDHL-6, and
SC-1) showed a mitochondrial response to the BAD peptide (Figure 4A), which could indicate that cells
had become more dependent on BCL-2 after CHOP treatment. Apart from responses to BAD, three cell
lines showed a strong response to the HRK peptide (SUDHL-2, OCI-LY3, and SUDHL-4) (Figure 4B),
which could indicate enhanced dependency on BCL-XL, and two cell lines (SUDHL-5 and SUDHL-10)
showed a response to the NOXA peptide (Figure 4C), which could indicate enhanced dependency
on MCL-1 after CHOP treatment. Combined, these data suggest that CHOP treatment altered the
BCL-2 dependency of cell lines OCI-LY3 and SUDHL-4 towards BCL-XL dependency, and made the
anti-apoptotic independent cell line SUDHL-2 dependent on BCL-XL (Figure 4D). In the other cell
lines, the cell specific anti-apoptotic dependency remained the same, however, it was further enhanced.
None of these CHOP-induced changes were related to a specific cell of origin (COO) or BCL2/MYC
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status, suggesting that changes are COO and BCL-2/MYC independent. Taken together, these data
demonstrate that CHOP chemotherapy not only enhances the anti-apoptotic dependency, it can also
alter the anti-apoptotic dependency, demonstrating that upfront expression levels of anti-apoptotic
proteins are insufficient to predict successful combination with anti-apoptotic inhibitors.
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(10 µg/mL) after treatment with CHOP for 18 h for BAD, HRK (B) and NOXA (C). Delta mitochondrial 
outer membrane permeabilization (ΔMOMP%) was calculated by subtracting the percentage treated 
MOMP from percentage untreated MOMP. Data were plotted as the mean ± SD (n = 3). Statistical 
analysis was performed with a one-sample T-test (* p ≤ 0.05) (** p ≤ 0.01). (D) Schematic overview of 
the anti-apoptotic dependency in DLBCL cell lines before and after CHOP treatment. White = no 
specific dependency (N.A.), blue = BLC-2 dependency, red = BCL-XL dependency, and green = MCL-
1 dependency. 
2.5. CHOP Chemotherapy Enhances Sensitivity to Anti-Apoptotic Inhibitors 
To validate that CHOP treatment enhances or alters the cell specific dependency on anti-
apoptotic proteins, we tested the combination of CHOP chemotherapy with venetoclax (BCL-2i), 
navitoclax (BCL-2/BCL-XL/BCL-Wi), or S63845 (MCL-1i) in the cell lines SC-1 (enhanced BCL-2 
dependency), SUDHL-4 (altered BCL-2  BCL-XL dependency), and SUDHL-10 (enhanced MCL-1 
dependency). 
Treatment with CHOP induced a dose-dependent enhanced sensitivity to venetoclax in cell lines 
SC-1 and SUDHL-4 (Figure S5), resulting in a decrease in IC50 values for venetoclax (Figure 5A) and 
overall strong synergism for the combination of CHOP with venetoclax (Figure 5B). A similar effect was 
observed when CHOP was combined with navitoclax, which also induced a decrease in IC50 values 
(Figure 5C) and overall strong synergism (Figure 5D) in cell lines SC-1 and SUDHL-4. These changes 
Figure 4. Dynamic BH3 profiles of DLBCL cell lines treated with CHOP chemotherapy. (A) Dynamic
BH3 profiles for the DLBCL cell lines OCI-LY3 (1 µg/mL), U-2932 (10 µg/mL), SUDHL-2 (1 µg/mL),
SUDHL-4 (10 µg/mL), SUDHL-5 (0.1 µg/mL), SUDHL-6 (1 µg/mL), SUDHL-10 (10 µg/mL), and SC-1
(10 µg/mL) after treatment with CHOP for 18 h for BAD, HRK (B) and NOXA (C). Delta mitochondrial
outer membrane permeabilization (∆MOMP%) was calculated by subtracting the percentage treated
MOMP from percentage untreated MOMP. Data were plotted as the mean ± SD (n = 3). Statistical
analysis was performed with a one-sample T-test (* p ≤ 0.05) (** p ≤ 0.01). (D) Schematic overview
of the anti-apoptotic dependency in DLBCL cell lines before and after CHOP treatment. White =
no specific dependency (N.A.), blue = BLC-2 dependency, red = BCL-XL dependency, and green =
MCL-1 dependency.
2.5. CHOP Chemotherapy Enhances Sensitivity to Anti-Apoptotic Inhibitors
To validate that CHOP treatment enhances or alters the cell specific dependency on anti-apoptotic
proteins, we tested the combination of CHOP chemotherapy with venetoclax (BCL-2i), navitoclax
(BCL-2/BCL-XL/BCL-Wi), or S63845 (MCL-1i) in the cell lines SC-1 (enhanced BCL-2 dependency),
SUDHL-4 (altered -2→ BCL-XL dependency), and SUDHL-10 (enha ced MCL-1 depen ency).
Treatment with CHOP induced a dose-dependent enhanced se sitivity to venetocl x in cell lines
SC-1 and SUDHL-4 (Figure S5), resulting in a decrease in IC50 values for venetoclax (Figure 5A) and
overall strong synergism for the combination of CHOP with venetoclax (Figure 5B). A similar effect
was observed when CHOP was combined with navitoclax, which also induced a decrease in IC50
values (Figure 5C) and overall strong synergism (Figure 5D) in cell lines SC-1 and SUDHL-4. These
chang s wer not observed in cell line SUDHL-10, s predicted by dynamic BH3 profiling. Instead,
SUDHL-10 showed a strong decrease in IC50 values for S63845 (Figure 5E) and overall strong synergism
Int. J. Mol. Sci. 2019, 20, 6036 8 of 15
for the combination of CHOP with S63845 (Figure 5F). Together, these data demonstrate that CHOP
chemotherapy can significantly enhance the effectivity of anti-apoptotic inhibitors in DLBCL.
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investigated whether CHOP treatment would alter the expression levels of anti-apoptotic proteins 
BCL-2, MCL-1, or BCL-XL (Figure 6). 
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t e co bination index (CI) from metaboli activity data for the venetoclax and CHOP combi ation
t erapy. Synergism was calculated with the Chou–Talalay method using CompuSyn. Synergistic
c binations are depicted in green (CI < 1.0), additive combinations are depicted in white (CI = 1.0),
and antagonistic combinations are depicted in red (CI > 1.0). ( ) IC50 values for navitoclax and CHOP
co bination therapy calculated fro metabolic activity data in SC-1, SUDHL-4, and SUDHL-10. Cells
were treated for 72 h and data were normalized to control. Data were plotted as the mean ± SD (n = 3).
(D) Synergism calculations from metabolic activity data for the navitoclax and CHOP combination
therapy (n = 3). (E) IC50 values for S63845 and CHOP combination therapy calculated from metabolic
activity data in cell lines SC-1, SUDHL-4, and SUDHL-10. Cells were treated for 72 h and data were
normalized to control. Data were plotted as the mean ± SD (n = 3). (F) Synergism calculations from
metabolic activity data for the S63845 and CHOP combination therapy (n = 3).
In addition to testing the synergy for CHOP together with anti-apoptotic inhibitors, we also
investigated whether CHOP treatment would alter the expression levels of anti-apoptotic proteins
BCL-2, MCL-1, or BCL-XL (Figure 6).
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CHOP treatment. Similarly, no changes were observed in MCL-1 protein expression after CHOP 
treatment in SUDHL-10, despite the strong dynamic BH3 response and enhanced sensitivity for 
MCL-1 inhibitor S63845. However, protein expression of BCL-XL was increased after CHOP 
treatment in both SC-1 and SUDHL-4, but not in SUDHL-10. These findings are in line with the 
observed HRK response in the BH3 profile found in SUDHL-4, although an increased HRK response 
was not observed in SC-1. These results suggest that while CHOP treatment can change expression 
levels of anti-apoptotic proteins, these changes may not accurately reflect the dependency of cells on 
these anti-apoptotic proteins. 
In conclusion, we were able to validate that CHOP treatment enhances the dependency on anti-
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Therefore, performing functional assays such as dynamic BH3 profiling is essential to establish how 
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In previous experiments we demonstrated that CHOP chemotherapy can greatly alter or 
enhance the dependency on anti-apoptotic proteins, resulting in synergism with anti-apoptotic 
inhibitors. However, since CHOP chemotherapy is composed of cyclophosphamide (C), doxorubicin 
(H), vincristine (O) or prednisolone (P), it remains unclear which of these compounds is responsible 
for the induced effects. We therefore tested each individual compound at the representative dosage 
of 10 µg/mL CHOP in a clinical ratio of 83/5.5/0.16/11.1, respectively [12] in the representative cell 
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Figure 7. Dynamic BH3 profiles of SC-1 treated with individual CHOP compounds. Dynamic BH3 
profile of (A) BIM and (B) BAD in the SC-1 cell line treated for 18 h with 10 µg/mL CHOP, 31.7 µM 
cyclophosphamide, 18 nM vincristine, 1 µM doxorubicin, or 3.18 µM prednisolone. Delta 
mitochondrial outer membrane permeabilization (ΔMOMP%) was calculated by subtracting the 
percentage treated MOMP from the percentage untreated MOMP. Data were plotted as the mean ± 
SD (n = 3). Statistical analysis was performed using a one-sample T-test (** p ≤ 0.01). 
Dynamic BH3 profiling of cells treated with vincristine or doxorubicin showed a similar 
response to the BIM (Figure 7A) and BAD (Figure 7B) peptide when compared to the full CHOP 
regimen, albeit somewhat lower. The combined effects for vincristine and doxorubicin on BIM (BIM 
Δ38% + Δ4% = Δ52%) were similar compared to the effects induced by CHOP (BIM Δ54%), which 
was also observed for BAD (BAD Δ49% + Δ23% = Δ72% vs. Δ63% by CHOP). No changes were 
induced by cyclophosphamide or prednisolone. So, although the greatest effect on anti-apoptotic 
dependency is achieved with complete CHOP, the bulk of the effect can likely be attributed to the 
actions of vincristine and doxorubicin, indicating that vincristine and doxorubicin are suitable 
chemotherapeutics in combination with BH3 mimetic drugs. 
3. Discussion 
While the relationship between BCL-2 expression and CHOP therapy resistance is well 
established [13,14], it has remained unclear how CHOP treatment affects anti-apoptotic proteins in 
DLBCL. Using functional BH3 profiling, we showed for the first time that CHOP treatment enhances 
dependency on anti-apoptotic proteins, making cells more sensitive to BH3 mimetic drugs, most 
likely through vincristine and/or doxorubicin. We also confirmed that CHOP treatment increases the 
sensitivity of DLBCL cells to BH3 mimetics, highlighting the potential for clinical applications. 
Furthermore, our findings highlighted the heterogeneity of anti-apoptotic dependency in DLBCL, in 
that CHOP treatment resulted in enhanced dependency, not only on BCL-2, but also on MCL-1 and 
BCL-XL. Since we found similar heterogeneity of anti-apoptotic expression in DLBCL patients, it 
seems plausible that in patients a similar enhanced or altered pattern on anti-apoptotic proteins might 
occur. A recent study by Smith et al. confirms this heterogeneity in DLBCL, as they demonstrated in 
a similar fashion how DLBCL cell lines show specific dependency on either BCL-2, BCL-XL, or MCL-
1 for survival [15]. None of the observed changes were related to a specific COO in our DLBCL cell 
line panel, indicating that initial inhibitor sensitivity or CHOP-induced anti-apoptotic changes might 
not be related to the differentiation stadium at which DLBCL might occur. In addition, we observed 
anti-apoptotic changes after CHOP treatment in both ‘double-hit’ (double MYC/BCL-2 translocation) 
and non-hit cell lines. It has been recently suggested that BCL-2, but not MCL-1, inhibition is effective 
Figure 7. Dynamic BH3 profiles of SC-1 treated with individual CHOP compounds. Dynamic BH3
profile of (A) BIM and (B) BAD in the SC-1 cell line treated for 18 h with 10 µg/mL CHOP, 31.7 µM
cyclophosphamide, 18 nM vincristine, 1 µM doxorubicin, or 3.18 µM prednisolone. Delta mitochondrial
outer membrane permeabilization (∆MOMP%) was calculated by subtracting the percentage treated
MOMP from the percentage untreated MOMP. Data were plotted as the mean ± SD (n = 3). Statistical
analysis was performed using a one-sample T-test (** p ≤ 0.01).
Dynamic BH3 profili g of cells tr ated with vincristine or doxorubicin showed a similar response
to the BIM (Figure 7A) and BAD (Figure 7B) peptide when compared to the full CHOP regimen,
albeit somewhat lower. The combined effects for vincristine and doxorubicin on BIM (BIM ∆38% +
∆4% = ∆52%) were similar compared to the effects induced by CHOP (BIM ∆54%), which was also
observed for BAD (BAD ∆49% + ∆23% = ∆72% vs. ∆63% by CHOP). No changes were induced by
cyclophosphamide or prednisolone. So, although the greatest effect on anti-apoptotic dependency
is achieved with complete CHOP, the bulk of the effect can likely be attributed to the actions of
vincristine and doxorubicin, indicating that vincristine and doxorubicin are suitable chemotherapeutics
in combination with BH3 mimetic drugs.
3. Discussion
While the relationship between BCL-2 expression and CHOP therapy resistance is well
established [13,14], it has remained unclear how CHOP treatment affects anti-apoptotic proteins
in DLBCL. Using functional BH3 profiling, we showed for the first time that CHOP t atme t nhanc s
dependency on anti-apoptotic protei s, making cells mo sensitive to BH3 mimetic drugs, most
likely through vi cristine and/o doxorubicin. We also confirmed that CHOP treatment increases
th sensitivity of DLBCL cells to BH3 mi etics, highlighting the potential for clinical application .
Furtherm re, our findi gs highlighted the heterogeneity of anti-apoptotic depend cy in DLBCL,
in that CHOP treatment resulted in enhanced dependency, not only on BCL-2, but lso on MCL-1
and BCL-XL. Since we found similar heterog neity of anti-apoptotic expression i DLBCL patients, it
seems plausible that in patients a simil r enhanced or altered pattern on anti-apoptotic proteins might
occur. A recent study by Smith et al. confirms this heterogeneity in DLBCL, as they demonstrat d in a
similar fashion how DLBCL cell lines show spe ific dep ndency on either BCL-2, BCL-XL, or MCL-1
f r survival [15]. None of the observed changes were elated to a specific COO in our DLBCL cell
line panel, indicating that initial inhibitor sensitivity or CHOP-induced anti-apoptotic changes might
not be related to the diff rentiati n stadium t which DLBCL might occur. In addition, we observed
anti-apoptotic changes after CHOP treatment in both ‘double-hit’ (double MYC/BCL-2 tr slocation)
and non-hit cell lines. It has been recently suggested that BCL-2, but n t MCL-1, inhibition is effective
in double-hit DLBCL [16]. However, as we have shown that double-hit status does not always match
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protein expression (e.g., SUDHL-10 lacks BCL-2 expression), this could result in ineffective treatment.
In fact, we saw an effective response to MCL-1 inhibitor treatment in the BCL-2/MYC double-hit
SUDHL-10 cell line, both prior to CHOP treatment and after CHOP treatment, whereas no response
was observed to BCL-2 inhibition. Although our data are broadly in line with recently published
clinical trial data for venetoclax in NHL [8], we found a potential impact for MCL-1 dependency after
CHOP treatment, which might indicate that a significant number of patients would derive greater
benefit from a MCL-1 inhibitor than from venetoclax treatment.
Robust immunohistological chemical staining for BCL-2 expression and the prognosis of R-CHOP
treated patients are both well established. However, as this is not the case for MCL-1 and other BCL-2
family members, it is still impossible to predict the prognosis of R-CHOP-treated patients based on the
expression of anti-apoptotic proteins. Alternatively, dynamic BH3 profiling would be a very useful
tool to predict an anti-apoptotic response to CHOP chemotherapy when applied to treatment-naïve
fresh DLBCL patient samples. However, in routine clinical practice, dynamic BH3 profiling of DLBCL
samples is challenging, as tissue samples are scarce and dividing cells are required in order to observe
possible effects of chemotherapy (e.g., CHOP) on the subsequent BH3 response in vitro. Ex vivo culture
of DLBCL is not possible without stimulation, and stimulation of cells (e.g., CD40 ligand) might skew
and alter the BH3 response to chemotherapy. Further research and optimization of BH3 profiling is
therefore warranted. In addition, in vivo experiments with either a patient-derived xenograft (PDX)
model or a spontaneous DLBCL mouse model should preferably be performed to predict and validate
the clinical applications of combining CHOP chemotherapy with a broad range of BH3 mimetic drugs.
Besides identifying MCL-1 and BCL-XL as novel contributors to CHOP-induced resistance, our data
also show the therapeutic potential of vincristine and doxorubicin in combination with BH3 mimetics.
In the current setting, the 10 µg/mL CHOP treatment contained single compound concentrations of
31.7 µM cyclophosphamide, 18 nM vincristine, 1 µM doxorubicin, and 3.18 µM prednisolone, which
are all within the range of clinical maximal plasma levels in patients (128 µM cyclophosphamide,
7 nM vincristine, 6.73 µM doxorubicin, and 0.145 µM prednisolone) [17]. At the moment, clinical
trials are underway regarding liposomal vincristine and venetoclax in relapsed or refractory T-cell or
B-cell NHL (NCT03504644/clinicaltrials.gov). Based on our data, we predict that both vincristine and
doxorubicin will induce changes in anti-apoptotic dependency, although whether changes will always
favor BCL-2 rather than MCL-1 or BCL-XL will remain unclear without functional dBH3 profiling.
In addition, additional experiments with higher concentrations of cyclophosphamide might induce
similar anti-apoptotic changes, which warrants further investigation for cyclophosphamide with BH3
mimetic drugs.
In conclusion, we demonstrated the potential of BH3 profiling as a predictor of anti-apoptotic
dependencies in DLBCL. Moreover, we showed that CHOP treatment induces increased anti-apoptotic
dependency, not only on BCL-2, but also on MCL-1 and BCL-XL. As a result, patient-specific BH3
mimetic treatment might well lead to synergistic lethality and reduce unnecessary treatment. Although
BCL-2 remains one of the primary actors in anti-apoptotic resistance, our results indicate that caution
is advisable and that other BH3 mimetics should not be neglected as they might well influence or alter
therapy outcomes.
4. Materials and Methods
4.1. Cell Lines and Culture Conditions
The DLBCL cell lines U-2932, SUDHL-2, SUDHL-4, and SC-1 were cultured in suspension
in Roswell Park Memorial Institute medium 1640 (RPMI 1640; Lonza BioWhittaker, Walkersville,
MD, USA) with 10% fetal bovine serum (FBS; HyClone Thermo Scientific, Waltham, MA, USA), 1%
penicillin-streptomycin (PS; Lonza BioWhittaker) and 1% glutamine (Lonza BioWhittaker). The DLBCL
cell lines OCILY3, SUDHL-5, SUDHL-6, and SUDHL-10 were cultured in suspension in RPMI 1640
with 20% FBS, 1% PS, and 1% glutamine. All cell lines were cultured at 37 ◦C with 5% CO2 in a
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humidified atmosphere. Cell lines were obtained from ATCC and DSMZ. The identity of our cell lines
was checked on a regular basis. Cell of origin (COO), BCL-2, and MYC status was based on data from
ATCC and DSMZ.
4.2. Patient Material
Patient material was used from 55 DLBCL patients with primary DLBCL, including most subtypes.
Material was acquired in accordance with international regulations and professional guidelines (the
Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good
Clinical Practice). Material used in this project (RR#201800551, 1 November 2018) was obtained from
anonymous rest material. The medical ethics review board (Central Ethics Review Board non-WMO
studies, University Medical Center Groningen (UMCG)) waives the need for approval if rest material
is used, under the law in the Netherlands and waives the need for informed consent when patient
anonymity is assured.
4.3. Immunohistochemistry (IHC)
IHC was performed with antibodies against BCL-2 (M0887, Dako, Glostrup, Denmark), BCL-XL
(SC7195, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MCL-1(A3534, Dako, Glostrup, Denmark)
on paraffin-embedded tissue sections after antigen retrieval (pH 6, pH 9, and pH 6, respectively).
Staining was visualized using HRP-labeled secondary antibodies (Dako) and 3,3′-diaminobenzidine
(Sigma–Aldrich, St Louis, MO, USA). Appropriate positive and negative controls were performed for
each staining. The cases were stained and scored on a tissue micro-array (TMA). In the TMA, each case
was represented by three tissue cores.
4.4. Compounds
The BCL-2 inhibitor venetoclax (#S8048, Houston, TX, USA), the BCL-2/BCL-XL/BCL-W inhibitor
navitoclax (#S1001), and the MCL-1 inhibitor S63845 (#S8383) were all acquired from Selleckchem.
CHOP chemotherapy consisted of cyclophosphamide (University Medical Center Groningen (UMCG)
pharmacy, Groningen, The Netherlands), doxorubicin (#S1208, Selleckchem, Houston, TX, USA),
vincristine (UMCG pharmacy, Groningen, the Netherlands), and prednisolone (#S1737, Selleckchem),
in a composition set at the clinical ratio of 83/5.5/0.16/11.1, respectively (12).
4.5. BH3 Profiling-Plate-Based Assay
BH3 profiling is a method to functionally characterize the interplay between anti- and pro-apoptotic
proteins for a particular cell line by employing a panel of pro-apoptotic BH3 domain peptides to measure
specific anti-apoptotic protein reactions. Upon treatment with these peptides, the mitochondrial outer
membrane response can be measured by cytochrome c release from the mitochondria using flow
cytometry or as the altered mitochondrial membrane potential by measuring fluorescence emission
of the JC-1 dye in a plate-based assay [3]. The BIM peptide is a pro-apoptotic activator protein that
reacts with multiple anti-apoptotic BH-3 proteins and can be used to establish whether cells are able to
undergo intrinsic apoptosis [11]. To determine the specific anti-apoptotic dependency of a DLBCL
cell line, we looked at the mitochondrial response of cells to the pro-apoptotic sensitizers BAD, HRK,
NOXA, or MS1. Cells dependent on anti-apoptotic BCL-2 will release cytochrome c in response to the
BAD peptide, which interacts with BCL-2, BCL-XL, and BCL-W, but not HRK (which interacts only
with BCL-XL). If cells are dependent on BCL-XL, cytochrome c release will be observed in response
to both BAD and HRK peptides. Cells dependent on anti-apoptotic MCL-1 will show a response to
NOXA and MS1.
In order to establish the effect of CHOP with BH3, profiling cells were incubated at a density of 1.0
× 106 cells/mL for 18 h with CHOP. After incubation, cells were washed in mannitol experimental buffer
(150 mM D-mannitol (M9647 Sigma–Aldrich, 3050 Spruce St., St. Louis, MO, USA), 10 mM HEPES
(H3375 Sigma–Aldrich), 50 mM KCl (1.04936 Merck KGaA, Darmstadt, Germany), 20 nM EGTA (E4378
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Sigma–Aldirch), 20 nM EDTA (11280, Serva Electrophoresis GmbH, Carl-Benz-Str. 7, Heidelberg,
Germany), 0,1% bovine serum albumin (BSA) (11930 Serva Electrophoresis GmbH), 5 mM succinate
(1.00682 Merck KGaA) dissolved in dH2O, pH 7.5 (MEB)) and resuspended at 3.2 × 106 cells/mL in MEB.
The cell suspension was mixed 1:1 with 4 µM JC-1 permeabilization/staining solution (ENZ-52304, Enzo
Life Sciences, 10 Executive Blvd., Farmingdale, NY 11735, USA), 0.004% digitonin (1500 643, Boehringer
Mannheim GmbH, Mannheim, Germany), 20 mM β-mercaptoethanol (8.05740 Merck KGaA), and
40 µg/mL oligomycin (O4876, Sigma–Aldrich) prepared in MEB) and incubated at room temperature
for 10 min in the dark. BIM, PUMA, BAD, NOXA, HRK, BMF, and PUMA2A (JPT Peptide Technologies
GmbH, Volmerstrasse, Berlin, Germany) were prepared in MEB in a black flat-bottom non-treated
polystyrene 96-well plate (3915 Costar, Corning Incorporated, 2 Alfred Road, Kennebunk, ME, USA).
Peptide sequences used for the assay were identical to those described by Ryan and Letai [18]. Plates
were either used directly or sealed (Silverseal sealer, ref 676090, Greiner-Bio-One GmbH, Mayback
Str., Frickenhausen, Germany), frozen at −80 ◦C and thawed for one hour at room temperature before
use. Cells in permeabilization/staining solution were added to the plate 1:1 at a final volume of
100 µL and shaken for 15 s, followed by measurement of fluorescence (excitation 545 nm, emission
590 nm) every 5 min for 2 h at 30 ◦C (Varioskan). All experiments were performed in triplicate or
quadruplicate. Area under the curve (AUC) was calculated as the percentage mitochondrial outer
membrane permeabilization (MOMP) and normalized to PUMA2A (negative control) and FCCP
(positive control) with the formula:
1 − ((AUC sample − AUC FCCP) ÷ (AUC PUMA2A − AUC FCCP)) × 100% (1)
The dynamic BH3 profile (∆MOMP) was calculated by subtracting the percentage treated MOMP
from the percentage untreated MOMP. BH3 profiling with a mean ∆MOMP ≥ 20% were classified as
biologically relevant, even if they were not always statically significant, as they often lead to significant
enhanced sensitivity to BH3 mimetic drugs, indicating biological relevance.
4.6. Flow Cytometry—Cell Viability for IC50
For cell viability analysis, 0.2 × 106 cells/mL were treated for the appropriate times, washed with
1% BSA/PBS and resuspended in propidium iodide solution (P4170, Sigma). Samples were processed
on a BD FACSCalibur 2 and analyzed with ModFit LT (Verity Software House, version 4.1.7, Topsham,
ME, USA). Experiments were performed three times.
4.7. Resazurin—Metabolic Viability for Combination Therapies
After treatment of 0.4 × 106 cells/mL, 1/20th of the total volume of resazurin (AlamarBlue, Thermo
Fisher Scientific, Waltham, MA, USA) was incubated for nine hours prior to read-out (Varioskan,
excitation 560 nm, emission 590 nm). Experiments were performed 3 times.
4.8. Western Blot
Western blot was performed as previously described [19]. Primary antibodies used were anti-BIM
(1:1000, #2933 (C34C5) Cell Signaling Technology, Danvers, MA, USA), anti-MCL-1 (1:1000, #5453
(D35A5) Cell Signaling Technology), anti-BCL-2 (1:1000, ab32124 (E17), Abcam, Cambridge, United
Kingdom), and anti-BCL-XL (1:1000, #2764 (54H6) Cell Signaling Technology).
4.9. Statistical Analysis
Data were analyzed using Graphpad PRISM (version 5.0, GraphPad Software, San Diego, CA,
USA) software and tested for significant differences with a paired T-test. Correlation was analyzed
using Spearman’s correlation. Combination index (CI) was calculated using the Chou-Talalay method
and CompuSyn software (ComboSyn Inc, NJ, USA). * indicates p ≤ 0.05, ** indicates p ≤ 0.01, and ***
indicates p ≤ 0.001.
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